Novartis (NVS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.41
- EPS estimate
- $2.17
- EPS surprise
- +10.95%
- Revenue surprise
- +2.43%
- Revenue
- $14.4B
- Revenue estimate
- $14.1B
- Reported
- Jul 21, 2026
Novartis reported Q2 2026 results on July 21, 2026. Earnings per share were $2.41, beating the $2.17 estimate by 10.95%. Revenue was $14.4 billion against a $14.1 billion consensus, the highest in the table. Compared with Q2 2025, EPS was essentially flat against $2.42, while revenue rose about 2% from $14.1 billion.
The quarter followed a weaker Q1 2026, when EPS of $1.99 missed by 5.13% and fell about 13% year over year. Over the longer record, annual EPS rose every year, from $5.80 in 2022 to $6.62 in 2023, $7.81 in 2024 and $8.98 in 2025. Revenue grew more slowly: annual totals stayed near $50 billion from 2022 to 2024 before reaching $54.5 billion in 2025. The first half of 2026 adds up to $4.40 per share, about 6% below the same period of 2025. Novartis beat EPS estimates in 16 of the 20 quarters shown.
Novartis reported Q3 between October 24 and October 29 in each of the past five years. That points to late October 2026 for the next report. It will show whether year-over-year earnings growth returns after a mixed first half.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 21, 2026 | $2.17 | $2.41 | +10.95% | $14.4B | SEC |
| Q1 2026 | Apr 28, 2026 | $2.10 | $1.99 | −5.13% | $13.1B | SEC |
| Q4 2025 | Feb 4, 2026 | $1.98 | $2.03 | +2.38% | $13.3B | SEC |
| Q3 2025 | Oct 28, 2025 | $2.27 | $2.25 | −1.00% | $13.9B | SEC |
| Q2 2025 | Jul 17, 2025 | $2.35 | $2.42 | +2.94% | $14.1B | SEC |
| Q1 2025 | Apr 29, 2025 | $2.11 | $2.28 | +7.86% | $13.2B | SEC |
| Q4 2024 | Jan 31, 2025 | $1.80 | $1.98 | +9.73% | $13.2B | SEC |
| Q3 2024 | Oct 29, 2024 | $1.94 | $2.06 | +6.27% | $12.8B | SEC |
| Q2 2024 | Jul 18, 2024 | $1.85 | $1.97 | +6.46% | $12.5B | SEC |
| Q1 2024 | Apr 23, 2024 | $1.68 | $1.80 | +7.29% | $11.8B | SEC |
| Q4 2023 | Jan 31, 2024 | $1.65 | $1.53 | −7.31% | $11.4B | SEC |
| Q3 2023 | Oct 24, 2023 | $1.67 | $1.74 | +4.37% | $11.8B | SEC |
| Q2 2023 | Jul 18, 2023 | $1.64 | $1.73 | +5.81% | $13.6B | SEC |
| Q1 2023 | Apr 25, 2023 | $1.45 | $1.62 | +11.61% | $13.0B | SEC |
| Q4 2022 | Feb 1, 2023 | $1.35 | $1.44 | +7.01% | $12.7B | SEC |
| Q3 2022 | Oct 25, 2022 | $1.47 | $1.50 | +1.89% | $12.5B | — |
| Q2 2022 | Jul 19, 2022 | $1.43 | $1.48 | +3.62% | $12.8B | — |
| Q1 2022 | Apr 26, 2022 | $1.38 | $1.38 | +0.51% | $12.5B | — |
| Q4 2021 | Feb 2, 2022 | $1.34 | $1.33 | −1.29% | $13.2B | — |
| Q3 2021 | Oct 26, 2021 | $1.55 | $1.62 | +4.51% | $13.0B | — |
Quarterly revenue
Frequently asked questions
When did Novartis (NVS) last report earnings?
Novartis last reported on Jul 21, 2026, covering fiscal Q2 2026.
Did NVS beat earnings estimates?
Yes. Novartis reported EPS of $2.41 for Q2 2026 against a $2.17 estimate — a 10.95% beat.
How much revenue did NVS report last quarter?
Novartis reported $14.4B in revenue for Q2 2026, against a consensus estimate of $14.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.